Abbott Laboratories
ABT
$107.45
-0.99%
Abbott Laboratories is a diversified healthcare manufacturer whose portfolio spans cardiovascular and diabetes devices (including pacemakers, implantable defibrillators, coronary stents, and continuous glucose monitors), core diagnostics and point-of-care testing, pediatric and adult nutritionals, and branded generic pharmaceuticals, with roughly 60% of sales generated outside the United States. As one of the largest and longest-tenured medical device and diagnostics franchises in the world — publicly listed since 1949 and employing approximately 115,000 people — Abbott occupies a scale-driven, defensive-growth niche rather than a pure high-multiple medtech growth profile, competing across four distinct end markets that smooth cyclicality but dilute segment-level focus. The current investor narrative is dominated by the announced spin-off of the troubled nutrition business, which management and sell-side commentary frame as a catalyst to sharpen the portfolio around higher-growth medical devices and diagnostics, alongside a strong Q3 2026 print (revenue up 14.5% year over year) that has revived confidence after a difficult first half. Debate now centers on whether the leaner post-spin Abbott can sustain double-digit device and diagnostics growth and re-rate toward medtech peers, or whether margin pressure from tariffs, litigation, and a soft nutrition franchise will keep the stock anchored below its prior highs.…
ABT
Abbott Laboratories
$107.45
Related headlines
Investment Opinion: Should I buy ABT Today?
Rating: Hold with a constructive lean. The core thesis is that Abbott is a scaled, low-beta (0.537) defensive medtech franchise trading at 18.28x forward earnings — a discount to premium device peers — where the pending nutrition spin-off is a genuine catalyst to sharpen the portfolio around the 92% of segment revenue in Medical Devices ($5.83B) and Diagnostics ($6.20B), but where a collapsed 10.44% Q3 operating margin means the 18.3x multiple rests on an earnings normalization (forward EPS $7.94 vs. trailing $0.03) that has not yet appeared in reported results. The 23 Buy / 5 Hold / 0 Sell consensus and $118.91 average target (9.6% upside) support a positive directional view, but the modest implied return and the single Argus downgrade to Hold on October 27 argue the risk/reward is fair rather than compelling after the 28.47% six-month rally.
Supporting evidence is mixed but tilts positive on valuation and negative on profitability. On the positive side: revenue re-accelerated to 14.46% YoY in Q3 ($13.01B vs. $11.37B), gross margin improved to 56.75% from 55.75%, the forward PE of 18.28x and EV/Sales of 4.47x are modest for a diversified medtech leader, $6.757B of trailing free cash flow comfortably covers the $1.10B quarterly dividend at a 63.1% payout ratio (1.88% yield), and debt-to-equity of 0.289 with a 1.576 current ratio leaves the balance sheet with ample room to fund the spin internally. On the negative side: operating income fell to $1.358B (10.44% margin) from $2.057B (18.09%) a year earlier, net income halved to $920M (7.07% margin) from $1.644B (14.46%), SG&A of $4.27B plus $841M of other expenses and $350M of interest expense are running operating leverage the wrong way, and the stock remains down 16.05% over twelve months with a 38.05% maximum drawdown.
The biggest risks that could invalidate the thesis are (1) failure of the $7.94 forward EPS to materialize — if operating margin stays near 10.4% rather than recovering toward the high teens, the trailing 33.5x PE becomes the honest picture and the stock stays anchored below its $132.03 high; (2) spin-off execution risk, with separation costs and dis-synergies potentially delaying earnings normalization and the $100-$130 target spread (30%) signaling genuine sell-side uncertainty; and (3) sector sentiment contagion, as evidenced by Boston Scientific's cyberattack-driven guidance cut and ISRG's $450M settlement showing how fast medical-device sentiment can turn. This Hold would upgrade to Buy if operating margin recovers above 15% for two consecutive quarters or if the stock pulls back toward the $96-100 support shelf (implying ~20x on forward EPS with the spin catalyst intact); it would downgrade to Sell if revenue growth decelerates below 8% or if forward EPS guidance is cut below $7.00. Verdict: fairly valued — the 18.3x forward multiple is a modest discount to peers that is partly earned by below-peer margins, and the stock sits roughly 82% of the way through its 52-week range, leaving limited margin of safety but also limited downside to the $100 analyst low.
Sign up to view all
ABT 12-Month Price Forecast
The forward-looking view is balanced: the valuation (18.28x forward PE, 4.47x EV/Sales) is undemanding for a scaled medtech franchise, revenue is re-accelerating at 14.46%, and the nutrition spin-off is a concrete catalyst to remove the low-growth drag and enable re-rating toward device peers. But the entire thesis hinges on earnings normalization — the gap between trailing EPS of $0.03 and forward consensus of $7.94 is enormous, and Q3 operating margin of 10.44% versus 18.09% a year earlier shows the recovery has not yet begun in reported numbers. The low beta of 0.537 and 1.88% covered dividend provide a defensive floor, and the $100 analyst low target limits quantified downside to roughly 8%, but the 28.47% six-month rally has already captured much of the easy re-rating. I would upgrade to bullish if operating margin recovers above 15% for two consecutive quarters or the stock pulls back to the $96-100 support shelf with the spin catalyst intact; I would downgrade to bearish if forward EPS guidance is cut below $7.00 or revenue growth decelerates below 8%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $118.91 and implied upside of +10.7% versus the current price.
Average Target
$118.91
28 analysts
Implied Upside
+10.7%
vs. current price
Analyst Count
28
covering this stock
Price Range
$100 - $130
Analyst target range
Coverage is deep and overwhelmingly constructive: 26 analysts rate the stock, with 23 Buy, 5 Hold, and 0 Sell, producing a consensus recommendation of "buy" and a recommendation mean of 1.54 (where 1.0 is a strong buy). The average target price of $118.91 implies roughly 9.6% upside from the current $108.52, a moderate rather than aggressive expected return that reflects the stock's already-substantial six-month rally; the consensus leans clearly bullish on direction but only modestly so on near-term magnitude.\n\nThe target range of $100.00 to $130.00 is moderately wide (a 30% spread from low to high), signaling meaningful dispersion in assumptions about the spin-off execution and earnings normalization. The $130 high target likely assumes successful separation of nutrition, sustained double-digit device and diagnostics growth (CGM, structural heart), margin recovery toward the high-teens operating level, and multiple expansion toward premium medtech peers; the $100 low target effectively prices in margin compression, integration missteps, or a slower-than-expected earnings recovery — notably, it sits only about 8% below the current price, implying limited downside even in the bear case. Institutional ratings show a stable-to-cautious pattern: the October 22 post-earnings wave featured reaffirmations (Wells Fargo Overweight, JP Morgan Overweight, Citigroup Buy, RBC Outperform, Baird Outperform, BTIG Buy, TD Cowen Buy) with no downgrades, but Argus Research cut to Hold from Buy on October 27 — a single sentiment crack that, combined with the tight low-end target, suggests analysts see the risk/reward as fair rather than compelling after the recent run.
Bulls vs Bears: ABT Investment Factors
The bull case currently rests on stronger hard evidence: revenue is re-accelerating at 14.46% year over year, the forward PE of 18.28x is modest for a scaled medtech franchise, 23 of 26 analysts rate the stock Buy, and the nutrition spin-off is a concrete catalyst to remove the low-growth drag. The bear case is equally specific but more about trajectory than level: operating margin collapsed to 10.44% from 18.09% a year earlier, net margin halved to 7.07%, and the stock remains down 16.05% over twelve months despite a 28.47% six-month rally. The single most important tension is whether the forward EPS of $7.94 materializes — if acquisition integration, spin-off separation costs and interest expense normalize as consensus expects, the 18.3x forward multiple is cheap; if margin compression persists, the trailing 33.5x PE is the more honest picture and the stock stays anchored below its $132.03 high. On balance the evidence favors the bulls modestly, but the margin trajectory is the swing factor that will decide the thesis.
Bullish
- Q3 revenue re-accelerating at 14.5%: Q3 2026 revenue of $13.01 billion grew 14.46% year over year versus $11.37 billion in Q3 2025, with sequential build from $11.16B in Q1 to $12.59B in Q2. Medical Devices ($5.83B) and Diagnostics ($6.20B) together account for roughly 92% of the $15.90B disclosed segment total, so the growth engine is exactly the business the nutrition spin-off is designed to emphasize.
- Forward PE of 18.3x is a relative value: The forward PE of 18.28x, EV/EBITDA of 18.91x and EV/Sales of 4.47x sit at a discount to premium pure-play device peers despite a scaled, diversified franchise. The trailing PE of 33.5x is distorted by one-time items (trailing EPS of $0.03 versus $7.94 forward consensus), so the forward multiple is the correct anchor and it is not demanding.
- Analyst consensus firmly constructive: 23 of 26 analysts rate the stock Buy with zero Sells and a recommendation mean of 1.54, and the $118.91 average target implies 9.6% upside from $108.52. The $100 low target sits only about 8% below the current price, meaning even the bear case on the sell side implies limited downside.
- Nutrition spin-off sharpens portfolio: Nutrition ($2.26B) and Established Pharmaceuticals ($1.61B) are the slow-growth drags being separated out, leaving a leaner device-and-diagnostics company that could re-rate toward higher medtech peer multiples. Recent coverage (Motley Fool, Oct 26 and Oct 21) frames the spin as reinforcing the long-term dividend growth story.
Bearish
- Operating margin collapse to 10.4%: Q3 2026 operating income fell to $1.358 billion (10.44% margin) from $2.057 billion (18.09%) a year earlier, even as gross margin improved to 56.75% from 55.75%. SG&A of $4.27 billion, R&D of $920 million, $841 million of other expenses and $350 million of interest expense are running the operating leverage the wrong way.
- Net margin halved year over year: Q3 2026 net income of $920 million represented a 7.07% net margin versus $1.644 billion and 14.46% in Q3 2025. The forward EPS consensus of $7.94 versus trailing EPS of $0.03 requires a dramatic earnings normalization that has not yet shown up in reported results.
- Stock still down 16% over 12 months: Despite a 28.47% six-month rally, ABT is down 16.05% over the trailing year and 12.62% YTD, with a maximum drawdown of 38.05%. The 1-month gain of 5.39% versus SPY's -2.26% reads as mean reversion off an oversold base rather than a confirmed trend reversal.
- Valuation discount partly justified: The 18.16% operating margin and 14.72% net margin trail best-in-class device peers, and the nutrition overhang has suppressed the multiple. A 4.20x price-to-book and 4.94x PS are not cheap enough to be a deep-value cushion if earnings normalization disappoints.
ABT Technical Analysis
Abbott is in a recovery uptrend within a longer-term downtrend: the stock is down 16.05% over the trailing year and 12.62% year to date, yet has rallied 28.47% over the past six months, and at $108.52 it sits roughly 82% of the way through its 52-week range of $81.97 to $132.03. That positioning — well off the low but still 17.8% below the 52-week high — is characteristic of a stock rebuilding momentum rather than one pressing into overextended territory, and the 38.05% maximum drawdown underscores how violent the prior de-rating was. The recovery has been driven by a sharp inflection from the mid-July trough near $89, with the price stair-stepping higher through August and September before consolidating.\n\nShort-term momentum is clearly positive and accelerating relative to the tape: ABT is up 5.39% over the past month versus a 2.26% decline for SPY, a 7.65-point relative-strength spread, and the 3-month change of -2.45% is essentially flat against SPY's -2.83%, meaning the recent surge is doing the heavy lifting. The 1-month gain conflicts with the -16.05% 1-year and -12.62% YTD figures, a divergence that reads as mean reversion off an oversold base rather than a confirmed trend reversal — the 6-month relative strength of +26.34 points against SPY confirms Abbott has been a standout since May even as it lags on a 12-month basis (-28.32 points). The November 4 spike to $115.51 on elevated volume (the post-earnings reaction to the Q3 beat and spin-off news) marked the recent momentum peak, and the subsequent pullback to $108.52 suggests some digestion of that move.\n\nKey technical levels are well defined: support sits at the 52-week low of $81.97, with a secondary shelf around the $96-100 zone that contained the October pullback, while resistance is the $115.51 November high and then the $132.03 52-week peak. A decisive break above $115.51 would confirm the recovery as a new uptrend and open the path toward the prior high, whereas a failure and breakdown below $100 would reassert the dominant downtrend and put the $82 low back in play. Volatility is unusually low for an equity: beta of 0.537 implies roughly 46% less volatility than SPY, which supports larger position sizing for risk-parity purposes but also means the stock will likely lag in a broad risk-on melt-up; the short ratio of 1.95 indicates minimal short-seller pressure and limited squeeze fuel.
Beta
0.54
0.54x market volatility
Max Drawdown
-38.0%
Largest decline past year
52-Week Range
$82-$132
Price range past year
Annual Return
-17.7%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | +2.4% | -3.0% |
| 3m | -4.6% | -3.6% |
| 6m | +21.6% | -0.2% |
| 1y | -17.7% | +10.1% |
| ytd | -13.5% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Revenue is re-accelerating convincingly: Q3 2026 revenue of $13.01 billion grew 14.46% year over year versus $11.37 billion in Q3 2025, and the sequential cadence ($11.16B in Q1, $12.59B in Q2, $13.01B in Q3) shows steady build through the year. The segment mix explains the trajectory — Medical Devices at $5.83 billion and Diagnostics at $6.20 billion together account for roughly 92% of the disclosed $15.90 billion segment total, while Nutrition ($2.26 billion) and Established Pharmaceuticals ($1.61 billion) are the slower-growth drags that the announced spin-off is designed to remove. With consensus 2027 revenue estimated at $65.80 billion (range $63.75B-$66.93B), the growth trend supports the bull case that a leaner, device-and-diagnostics-focused Abbott can compound at a mid-to-high single-digit rate with upside from CGM and structural heart.\n\nProfitability is solid but under visible pressure at the operating line: Q3 2026 net income was $920 million on a 7.07% net margin, down sharply from $1.644 billion and a 14.46% net margin in Q3 2025, while gross margin actually improved to 56.75% from 55.75%. The culprit is operating leverage running the wrong way — operating income fell to $1.358 billion (10.44% operating margin) from $2.057 billion (18.09%) a year earlier, driven by SG&A of $4.27 billion and R&D of $920 million plus $841 million of other expenses and $350 million of interest expense tied to the $19.8 billion acquisition financing visible in Q1 investing cash flow. The 18.16% operating margin and 14.72% net margin on a TTM basis remain respectable for diversified medtech, but the compression trend bears watching; the forward EPS consensus of $7.94 versus trailing EPS of $0.03 (distorted by one-time items) implies the market expects a sharp normalization of earnings power.\n\nThe balance sheet is a genuine strength: debt-to-equity of 0.289 and a current ratio of 1.576 provide ample liquidity, while trailing free cash flow of $6.757 billion against a $218.9 billion market cap yields roughly 3.1% — modest but adequate for a dividend payer. ROE of 12.51% and ROA of 4.90% are healthy though below Abbott's historical norms, reflecting the acquisition-related balance sheet expansion; Q3 operating cash flow of $1.737 billion less $513 million of capex produced $1.224 billion of FCF, and the company returned $1.094 billion in dividends while repaying $1.4 billion of debt. The $1.10 billion quarterly dividend at a 63.1% payout ratio and 1.88% yield is well covered by cash generation, and the Q1 debt raise that funded acquisitions has been partially retired, leaving financial risk low — Abbott can fund growth internally without meaningful external financing dependence.
Quarterly Revenue
$13.0B
2026-09
Revenue YoY Growth
+14.5%
YoY Comparison
Gross Margin
56.8%
Latest Quarter
Free Cash Flow
$6.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Because trailing net income is positive but heavily distorted by one-time items (trailing EPS of $0.03 versus a $7.94 forward consensus), the trailing PE of 33.5x is not the right anchor; I lead with the forward PE of 18.28x, which is the metric that reflects normalized earnings power and is corroborated by EV/EBITDA of 18.91x and EV/Sales of 4.47x. The enormous gap between trailing (33.5x) and forward (18.3x) multiples implies the market expects earnings to roughly double as acquisition integration, spin-off separation costs, and interest expense normalize — a wide gap that embeds meaningful execution risk if that earnings recovery disappoints.\n\nAgainst the Medical-Devices industry, Abbott screens as a relative value: PS of 4.94x and EV/Sales of 4.47x are modest for a scaled medtech franchise, and the 18.28x forward PE sits at a discount to the premium multiples commanded by pure-play device peers, while the 4.20x price-to-book is unremarkable. The discount is partly justified — Abbott's 18.16% operating margin and 14.72% net margin trail best-in-class device peers, and the nutrition overhang has suppressed the multiple — but the pending spin-off is precisely the catalyst that could close the gap by removing the low-growth drag and allowing the remaining device/diagnostics business to be valued on higher peer multiples. The 1.88% dividend yield and 63.1% payout ratio add an income floor that pure-growth peers lack.\n\nHistorically, Abbott has traded in a wide PE band: the quarterly PE ratio ranged from roughly 5.3x (Q4 2024, distorted by a tax benefit) to 46.6x (Q3 2026, distorted by depressed earnings), with a more representative range of 30-35x in normal quarters such as Q3 2025 (35.6x) and Q2 2025 (33.3x). The current 33.5x trailing PE sits mid-band, while PS of 4.94x is near the low end of its multi-year range (which has run from roughly 12.6x to 22.4x on a quarterly basis, with the current reading reflecting the larger post-acquisition revenue base) — suggesting the market is not pricing in optimistic expectations and that the stock offers value if earnings normalize as consensus forecasts. The negative PEG ratio of -0.65 is a mechanical artifact of the trailing earnings distortion and should be disregarded in favor of the forward earnings trajectory.
PE
33.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 21x~47x
vs. Industry Avg
26.4x
Industry PE ~26.4x*
EV/EBITDA
18.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the sharp compression of profitability despite top-line strength. Q3 2026 operating income fell to $1.358 billion (10.44% margin) from $2.057 billion (18.09%) a year earlier, and net income dropped to $920 million (7.07% margin) from $1.644 billion (14.46%), driven by SG&A of $4.27 billion, R&D of $920 million, $841 million of other expenses and $350 million of interest expense tied to the $19.8 billion acquisition financing. The forward EPS consensus of $7.94 versus trailing EPS of $0.03 means the entire valuation depends on a dramatic earnings normalization that has not yet appeared in reported results, and the spin-off of nutrition will carry separation costs and dis-synergies that could delay it further. Balance-sheet risk is low — debt-to-equity of 0.289, current ratio of 1.576, and $6.757 billion of trailing free cash flow comfortably cover the $1.10 billion quarterly dividend at a 63.1% payout ratio — so the financial risk is earnings quality, not solvency.
Market and competitive risks are moderate given the low beta of 0.537, which implies roughly 46% less volatility than SPY but also means the stock will lag in a broad risk-on melt-up. The forward PE of 18.28x is a discount to premium device peers, but that discount is partly earned: an 18.16% operating margin and 14.72% net margin trail best-in-class medtech, and the 4.20x price-to-book offers little cushion. Sector rotation is a live threat — recent coverage of Boston Scientific's cyberattack-driven guidance cut and ISRG's $450 million settlement shows how quickly sentiment can turn in medical devices, and any read-across on procedure volumes or litigation would hit Abbott's device franchise. The single Argus downgrade to Hold on October 27, alongside a $100-$130 target spread, signals that sell-side conviction on the spin-off execution is not uniform.
In a worst-case scenario, the earnings normalization implied by the $7.94 forward EPS fails to materialize: spin-off separation costs run over, interest expense stays elevated, and operating margin remains near the 10.4% Q3 level rather than recovering toward the high teens. That would compress the multiple back toward the trailing 33.5x reality on depressed earnings and push the stock toward the $100 analyst low target, roughly 8% below the current $108.52, and in a broader de-rating toward the 52-week low of $81.97 — a decline of about 24.5% from current levels. The 38.05% maximum drawdown is the historical reminder of how violent the prior de-rating was, so a realistic adverse case is a 10-25% loss, with the $81.97 low as the hard floor reference.
FAQ
Ranked by severity: first, earnings-normalization risk — Q3 2026 operating income fell to $1.358B (10.44% margin) from $2.057B (18.09%), and the entire 18.3x forward multiple depends on EPS recovering to $7.94 from a trailing $0.03. Second, spin-off execution risk — separation costs and dis-synergies for the nutrition business could delay that recovery, reflected in the wide $100-$130 analyst target spread (30%). Third, sector sentiment risk — Boston Scientific's cyberattack-driven guidance cut and ISRG's $450M settlement show how fast medical-device sentiment can turn, and ABT's 0.537 beta offers only partial insulation. Fourth, valuation/momentum risk — after a 28.47% six-month rally the stock sits roughly 82% of the way through its 52-week range, leaving limited margin of safety, with a 38.05% historical maximum drawdown as a reminder of how violent the prior de-rating was. Balance-sheet risk is the least concerning, with debt-to-equity of 0.289 and $6.757B of trailing free cash flow covering the dividend at a 63.1% payout ratio.
The base case (50% probability) targets $115-$122, assuming forward EPS of $7.94 materializes as one-time items annualize out, operating margin recovers to roughly 14-16%, and the stock grinds toward the $118.91 analyst average as the forward PE holds near 18-19x. The bull case (30% probability) targets $125-$130, requiring a clean nutrition spin-off, margin recovery above 15%, and multiple expansion toward premium device peers, closing the gap to the $130 analyst high. The bear case (20% probability) targets $82-$100, where separation costs run over, margin stays near 10.4%, and the stock falls toward the $100 analyst low and potentially the $81.97 52-week low. The base case is most likely, and its key assumption is that the earnings normalization embedded in the $7.94 forward consensus actually shows up in reported results within the next 12 months.
The right anchor is the forward PE of 18.28x, not the trailing 33.5x, because trailing EPS of $0.03 is distorted by one-time items versus a $7.94 forward consensus. On that basis ABT screens as modestly undervalued relative to premium pure-play medtech peers, corroborated by EV/EBITDA of 18.91x and EV/Sales of 4.47x, though the 4.20x price-to-book and 4.94x PS offer little deep-value cushion. The discount is partly earned: an 18.16% operating margin and 14.72% net margin trail best-in-class device peers, and the nutrition overhang has suppressed the multiple. The wide gap between trailing and forward multiples implies the market expects earnings to roughly double as integration, spin-off separation costs and interest expense normalize — so the valuation is fair-to-slightly-cheap only if that recovery happens, and expensive if operating margin stays near 10.4%.
From a risk/reward standpoint ABT is a reasonable but not exceptional buy at $108.52: the $118.91 average analyst target implies about 9.6% upside, while the $100 low target sits only roughly 8% below the current price, giving a favorable but modest asymmetry. The bull case is anchored in 14.46% year-over-year revenue growth in Q3 2026, a forward PE of 18.28x that is a discount to premium device peers, and 23 of 26 analysts rating the stock Buy with zero Sells. The biggest downside risk is that the forward EPS of $7.94 fails to materialize — Q3 operating margin collapsed to 10.44% from 18.09%, and in a broader de-rating the stock could fall toward the $81.97 52-week low, roughly 24.5% below current levels. It is a good buy for patient, income-oriented investors who can tolerate a 12-24 month wait for margin recovery and the nutrition spin-off, and a less attractive buy for anyone chasing the 28.47% six-month rally who needs near-term upside.
ABT is better suited to long-term holding than short-term trading. Its beta of 0.537 implies roughly 46% less volatility than SPY, which limits the range available to traders, and the 1.88% dividend yield at a 63.1% payout ratio rewards patience with income while the earnings story plays out. The stock is in a recovery uptrend — up 28.47% over six months but still down 16.05% over twelve months and 12.62% YTD — so near-term momentum is positive but the longer trend is unproven, and the 38.05% maximum drawdown shows the downside can be sharp. Earnings visibility is currently low because reported margins are depressed and the spin-off timeline is unresolved, which argues against a short horizon. A concrete suggested minimum holding period is 12-24 months, long enough to capture the nutrition separation and at least two quarters of margin recovery above 15%.

